Short Interest in UCB SA (OTCMKTS:UCBJY) Declines By 97.9%

UCB SA (OTCMKTS:UCBJY) was the recipient of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 100 shares, a decrease of 97.9% from the December 31st total of 4,700 shares. Based on an average daily trading volume, of 19,300 shares, the days-to-cover ratio is presently 0.0 days.

UCB Price Performance

OTCMKTS UCBJY traded down $1.58 during trading hours on Friday, reaching $97.18. 26,891 shares of the company’s stock traded hands, compared to its average volume of 24,078. The firm has a 50-day simple moving average of $97.60 and a 200 day simple moving average of $92.36. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. UCB has a 52-week low of $46.00 and a 52-week high of $100.66.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.